
Protheragen
End-to-end preclinical and clinical CRO specializing in obesity therapeutics development.
Specialized preclinical CRO dedicated to obesity research, offering comprehensive animal models, pharmacokinetic/pharmacodynamic studies, bioanalysis, and safety assessment for anti-obesity drug development.
Phases
Indications / Therapeutic Areas
Services
- Discovery Research
- Target Identification & Validation
- Medicinal Chemistry
- Preclinical In Vitro Studies
- In Vitro Pharmacology
- In Vitro ADME / DMPK
- Safety Pharmacology
- Preclinical In Vivo Studies
- In Vivo Efficacy Models
- In Vivo PK / PD Studies
- GLP Toxicology
- Specialized & Large-Animal Models
- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Clinical Operations
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Pharmacovigilance & Drug Safety
- Medical Writing
- Regulatory Affairs
- US FDA Regulatory Strategy
Modalities
Technical specifications & accreditations
Accreditations
Infrastructure
About this organization
Protheragen is a contract research organization (CRO) focused exclusively on preclinical and clinical research for obesity therapeutics. The company provides an integrated obesity research platform spanning discovery, preclinical development, and clinical support services.
Core Capabilities
Preclinical Services:
- Obesity models that replicate obesity-related conditions
- Pharmacodynamic studies assessing biological effects and mechanisms of action
- Pharmacokinetic studies evaluating drug absorption, distribution, metabolism, and excretion
- Bioanalysis using advanced techniques to quantify drug concentrations
- Safety assessment and toxicological evaluation
- Custom research services tailored to client needs
Target Selection & Drug Development:
- Expertise across hormones and peptides (leptin, adiponectin, ghrelin, GLP-1, amylin, exendin)
- Receptor targeting (MC4R, PPARs, serotonin, cannabinoid, orexin, glucagon, GIP)
- Enzyme and protein targets
- Metabolic regulators and signaling molecules
- Mitochondrial targets
- Support for small molecule, gene therapy, cell therapy, antibody, tissue engineering, and nanotherapy modalities
Clinical & Regulatory Support:
- Regulatory affairs and submission support
- Clinical development strategy and medical writing
- Early phase clinical pharmacology
- Clinical operations and trial management
- Site management and patient recruitment
- Data management and biostatistics
- Pharmacovigilance and risk management
- Post-marketing evidence and market access (RWE/HEOR)
Commitment
Protheragen emphasizes GLP/GMP compliance, quality assurance, and regulatory acceptance of data. The company employs a multidisciplinary approach integrating metabolism, inflammation, and cardiovascular biology expertise, working collaboratively with clients to deliver tailored solutions that accelerate obesity drug development timelines.
Similar companies
Similar profiles by shared services, phases, and indications.
Frontage Laboratories- Discovery Research
- Target Identification & Validation
Certara- Discovery Research
- Target Identification & Validation
QPS- Preclinical In Vitro Studies
- In Vitro Pharmacology
Premier Research- Preclinical In Vitro Studies
- In Vitro Pharmacology
WuXi AppTec- Discovery Research
- Target Identification & Validation
Tigermed- Medicinal Chemistry
- Preclinical In Vitro Studies
Altasciences- Preclinical In Vitro Studies
- In Vitro Pharmacology
Allucent- Preclinical In Vitro Studies
- In Vitro Pharmacology
View all alternatives →See similar CROs ranked by shared capabilities
Submit a verified review for this organization.
Markdown mirror: /companies/obesityscientific.md